Contact
searchSearch
HMP Global
Login

Bladder Cancer Specialty Channel

Bladder Cancer
Specialty Channel
FDA Approval
FDA Grants Approval to Pembrolizumab With Enfortumab Vedotin for Muscle Invasive Bladder Cancer
11/21/2025
Gina Tomaine
On November 21, 2025, the FDA granted approval to pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph with enfortumab vedotin-ejfv as neoadjuvant treatment followed by adjuvant treatment after cystectomy for patients with muscle...
On November 21, 2025, the FDA granted approval to pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph with enfortumab vedotin-ejfv as neoadjuvant treatment followed by adjuvant treatment after cystectomy for patients with muscle...
On November 21, 2025, the FDA...
11/21/2025
Oncology
News
Circulating Tumor DNA-Guided Adjuvant Atezolizumab Significantly Improves Survival Otucomes in Bladder Cancer
10/20/2025
Stephanie Holland
Adjuvant atezolizumab guided by circulating tumor DNA status led to statistically significant and clinically meaningful improvements in disease-free and overall survival compared to placebo in high-risk muscle-invasive bladder cancer.
Adjuvant atezolizumab guided by circulating tumor DNA status led to statistically significant and clinically meaningful improvements in disease-free and overall survival compared to placebo in high-risk muscle-invasive bladder cancer.
Adjuvant atezolizumab guided by...
10/20/2025
Oncology
News
Disitamab Vedotin Plus Toripalimab Doubles Survival vs Chemotherapy in HER2-Expressing Metastatic Urothelial Carcinoma
10/19/2025
Janelle Bradley
First-line treatment with disitamab vedotin plus toripalimab significantly prolonged PFS and OS compared to standard platinum-based chemotherapy in patients with HER2-expressing locally advanced or metastatic urothelial carcinoma.
First-line treatment with disitamab vedotin plus toripalimab significantly prolonged PFS and OS compared to standard platinum-based chemotherapy in patients with HER2-expressing locally advanced or metastatic urothelial carcinoma.
First-line treatment with...
10/19/2025
Oncology
Nicholas James, MD, PhD
Videos
Clinical Impact of Upfront Multiparametric MRI on Staging Accuracy and Survival in Muscle-Invasive Bladder Cancer
10/19/2025
Nicholas James, MD
Nicholas James, MD, PhD, discusses results from the BladderPath trial comparing traditional TURBT-based staging with a multiparametric MRI–guided pathway staging system for suspected muscle-invasive bladder cancer.
Nicholas James, MD, PhD, discusses results from the BladderPath trial comparing traditional TURBT-based staging with a multiparametric MRI–guided pathway staging system for suspected muscle-invasive bladder cancer.
Nicholas James, MD, PhD,...
10/19/2025
Oncology
News
Perioperative Enfortumab Vedotin Plus Pembrolizumab Significantly Improves Survival in Muscle-Invasive Bladder Cancer
10/19/2025
Stephanie Holland
Results from the phase 3 KEYNOTE-905/EV-303 trial show perioperative enfortumab vedotin plus pembrolizumab significantly improved survival outcomes vs surgery alone in patients with muscle-invasive bladder cancer ineligible for...
Results from the phase 3 KEYNOTE-905/EV-303 trial show perioperative enfortumab vedotin plus pembrolizumab significantly improved survival outcomes vs surgery alone in patients with muscle-invasive bladder cancer ineligible for...
Results from the phase 3...
10/19/2025
Oncology
FDA Approval
FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer
09/10/2025
Allison Casey
On Tuesday, September 9, 2025, the FDA approved the use of a gemcitabine intravesical system, TAR-200, for the treatment of patients with Bacillus Calmette-Guérin–unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or...
On Tuesday, September 9, 2025, the FDA approved the use of a gemcitabine intravesical system, TAR-200, for the treatment of patients with Bacillus Calmette-Guérin–unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or...
On Tuesday, September 9, 2025,...
09/10/2025
Oncology
FDA Approval
Intravesical Mitomycin Approved for Low-Grade Non-Muscle Invasive Bladder Cancer
06/12/2025
Allison Casey
The US FDA approved mitomycin intravesical solution for patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.
The US FDA approved mitomycin intravesical solution for patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.
The US FDA approved mitomycin...
06/12/2025
Oncology
News
Cabozantinib Plus Atezolizumab for Patients With Advanced Urothelial Carcinoma
05/13/2025
Stephanie Holland
According to results from the phase 1b COSMIC-021 trial, cabozantinib plus atezolizumab demonstrated promising clinical efficacy and safety among patients with inoperable, locally advanced or metastatic urothelial carcinoma.
According to results from the phase 1b COSMIC-021 trial, cabozantinib plus atezolizumab demonstrated promising clinical efficacy and safety among patients with inoperable, locally advanced or metastatic urothelial carcinoma.
According to results from the...
05/13/2025
Oncology
Joseph Jacob, MD
Videos
TAR-200 Monotherapy Demonstrates Durability of Response in BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer
05/09/2025
Joseph Jacob, MD, discusses results from cohort 2 of the ongoing phase 2b SunRISe-1 trial which assessed the durability of response of TAR-200 monotherapy among patients with Bacillus Calmette-Guérin-unresponsive high-risk non-muscle invasive...
Joseph Jacob, MD, discusses results from cohort 2 of the ongoing phase 2b SunRISe-1 trial which assessed the durability of response of TAR-200 monotherapy among patients with Bacillus Calmette-Guérin-unresponsive high-risk non-muscle invasive...
Joseph Jacob, MD, discusses...
05/09/2025
Oncology
Felix Guerrero-Ramos, MD, PhD
Conference Coverage
TAR-200 for BCG-Unresponsive, Papillary-Only High-Risk Non-Muscle Invasive Bladder Cancer
04/28/2025
Felix Guerrero-Ramos, MD, PhD
Felix Guerrero-Ramos, MD, PhD discusses first results from cohort 4 of the phase 2b SunRISe-1 trial which assessed TAR-200 monotherapy in patients with BCG-unresponsive, papillary-only high-risk non-muscle invasive bladder cancer.
Felix Guerrero-Ramos, MD, PhD discusses first results from cohort 4 of the phase 2b SunRISe-1 trial which assessed TAR-200 monotherapy in patients with BCG-unresponsive, papillary-only high-risk non-muscle invasive bladder cancer.
Felix Guerrero-Ramos, MD, PhD...
04/28/2025
Oncology
News
Sacituzumab Govitecan Fails to Significantly Improve Survival in Advanced Urothelial Carcinoma
04/17/2025
Stephanie Holland
According to final analysis results from the phase 3 TROPICS-04 trial, sacituzumab govitecan did not significantly improve survival among previously treated patients with advanced urothelial carcinoma.
According to final analysis results from the phase 3 TROPICS-04 trial, sacituzumab govitecan did not significantly improve survival among previously treated patients with advanced urothelial carcinoma.
According to final analysis...
04/17/2025
Oncology

News

News
Circulating Tumor DNA-Guided Adjuvant Atezolizumab Significantly Improves Survival Otucomes in Bladder Cancer
10/20/2025
Stephanie Holland
Adjuvant atezolizumab guided by circulating tumor DNA status led to statistically significant and clinically meaningful improvements in disease-free and overall survival compared to placebo in high-risk muscle-invasive bladder cancer.
Adjuvant atezolizumab guided by circulating tumor DNA status led to statistically significant and clinically meaningful improvements in disease-free and overall survival compared to placebo in high-risk muscle-invasive bladder cancer.
Adjuvant atezolizumab guided by...
10/20/2025
Oncology
News
Disitamab Vedotin Plus Toripalimab Doubles Survival vs Chemotherapy in HER2-Expressing Metastatic Urothelial Carcinoma
10/19/2025
Janelle Bradley
First-line treatment with disitamab vedotin plus toripalimab significantly prolonged PFS and OS compared to standard platinum-based chemotherapy in patients with HER2-expressing locally advanced or metastatic urothelial carcinoma.
First-line treatment with disitamab vedotin plus toripalimab significantly prolonged PFS and OS compared to standard platinum-based chemotherapy in patients with HER2-expressing locally advanced or metastatic urothelial carcinoma.
First-line treatment with...
10/19/2025
Oncology
Nicholas James, MD, PhD
Videos
Clinical Impact of Upfront Multiparametric MRI on Staging Accuracy and Survival in Muscle-Invasive Bladder Cancer
10/19/2025
Nicholas James, MD
Nicholas James, MD, PhD, discusses results from the BladderPath trial comparing traditional TURBT-based staging with a multiparametric MRI–guided pathway staging system for suspected muscle-invasive bladder cancer.
Nicholas James, MD, PhD, discusses results from the BladderPath trial comparing traditional TURBT-based staging with a multiparametric MRI–guided pathway staging system for suspected muscle-invasive bladder cancer.
Nicholas James, MD, PhD,...
10/19/2025
Oncology
News
Perioperative Enfortumab Vedotin Plus Pembrolizumab Significantly Improves Survival in Muscle-Invasive Bladder Cancer
10/19/2025
Stephanie Holland
Results from the phase 3 KEYNOTE-905/EV-303 trial show perioperative enfortumab vedotin plus pembrolizumab significantly improved survival outcomes vs surgery alone in patients with muscle-invasive bladder cancer ineligible for...
Results from the phase 3 KEYNOTE-905/EV-303 trial show perioperative enfortumab vedotin plus pembrolizumab significantly improved survival outcomes vs surgery alone in patients with muscle-invasive bladder cancer ineligible for...
Results from the phase 3...
10/19/2025
Oncology
News
Cabozantinib Plus Atezolizumab for Patients With Advanced Urothelial Carcinoma
05/13/2025
Stephanie Holland
According to results from the phase 1b COSMIC-021 trial, cabozantinib plus atezolizumab demonstrated promising clinical efficacy and safety among patients with inoperable, locally advanced or metastatic urothelial carcinoma.
According to results from the phase 1b COSMIC-021 trial, cabozantinib plus atezolizumab demonstrated promising clinical efficacy and safety among patients with inoperable, locally advanced or metastatic urothelial carcinoma.
According to results from the...
05/13/2025
Oncology
Felix Guerrero-Ramos, MD, PhD
Conference Coverage
TAR-200 for BCG-Unresponsive, Papillary-Only High-Risk Non-Muscle Invasive Bladder Cancer
04/28/2025
Felix Guerrero-Ramos, MD, PhD
Felix Guerrero-Ramos, MD, PhD discusses first results from cohort 4 of the phase 2b SunRISe-1 trial which assessed TAR-200 monotherapy in patients with BCG-unresponsive, papillary-only high-risk non-muscle invasive bladder cancer.
Felix Guerrero-Ramos, MD, PhD discusses first results from cohort 4 of the phase 2b SunRISe-1 trial which assessed TAR-200 monotherapy in patients with BCG-unresponsive, papillary-only high-risk non-muscle invasive bladder cancer.
Felix Guerrero-Ramos, MD, PhD...
04/28/2025
Oncology
News
Sacituzumab Govitecan Fails to Significantly Improve Survival in Advanced Urothelial Carcinoma
04/17/2025
Stephanie Holland
According to final analysis results from the phase 3 TROPICS-04 trial, sacituzumab govitecan did not significantly improve survival among previously treated patients with advanced urothelial carcinoma.
According to final analysis results from the phase 3 TROPICS-04 trial, sacituzumab govitecan did not significantly improve survival among previously treated patients with advanced urothelial carcinoma.
According to final analysis...
04/17/2025
Oncology
FDA Approval
Durvalumab Approved for Muscle Invasive Bladder Cancer
03/31/2025
Allison Casey
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant...
03/31/2025
Oncology
Thomas Powles, MBBS, MD
Conference Coverage
Continued Efficacy With Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Carcinoma
02/18/2025
Thomas Powles, MBBS, MD
Thomas Powles, MD, MBBS, discusses the updated analysis of the EV-302 trial which found that enfortumab vedotin plus pembrolizumab continued to show superior efficacy compared with chemotherapy among patients with locally advanced or...
Thomas Powles, MD, MBBS, discusses the updated analysis of the EV-302 trial which found that enfortumab vedotin plus pembrolizumab continued to show superior efficacy compared with chemotherapy among patients with locally advanced or...
Thomas Powles, MD, MBBS,...
02/18/2025
Oncology
Conference Coverage
Durvalumab Plus Intravesical Chemotherapy for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
02/13/2025
Allison Casey
According to results from the phase 1/2 ADAPT-BLADDER trial, durvalumab plus intravesical gemcitabine and docetaxel showed promising clinical efficacy with high response rates among patients with BCG-unresponsive non-muscle invasive bladder...
According to results from the phase 1/2 ADAPT-BLADDER trial, durvalumab plus intravesical gemcitabine and docetaxel showed promising clinical efficacy with high response rates among patients with BCG-unresponsive non-muscle invasive bladder...
According to results from the...
02/13/2025
Oncology

Interactive Features

Quiz
Enfortumab Vedotin for Patients With Advanced Urothelial Carcinoma
10/19/2023
True or False: According to findings from the phase 3 EV-301 trial, enfortumab vedotin maintained clinically meaningful overall survival benefit at a median follow-up of approximately 2 years, compared with chemotherapy, among patients with...
True or False: According to findings from the phase 3 EV-301 trial, enfortumab vedotin maintained clinically meaningful overall survival benefit at a median follow-up of approximately 2 years, compared with chemotherapy, among patients with...
True or False: According to...
10/19/2023
Oncology
Quiz
NECTIN-4 Expression During Metastatic Spread in Urothelial Carcinoma
02/10/2023
In a study evaluating the changes in membranous NECTIN-4 protein expression among urothelial carcinoma progression, what percentage of cases demonstrated a decrease of NECTIN-4 expression during metastatic spread?
In a study evaluating the changes in membranous NECTIN-4 protein expression among urothelial carcinoma progression, what percentage of cases demonstrated a decrease of NECTIN-4 expression during metastatic spread?
In a study evaluating the...
02/10/2023
Oncology
Quiz
Quiz: Rogaratinib Compared With Standard Chemotherapy for FGFR-Altered Urothelial Carcinoma
12/01/2022
In the open-label, multicenter FORT-1 trial, how did the pan-FGFR inhibitor rogaratinib compare to standard chemotherapy, in terms of efficacy in treating patients with FGFR-altered urothelial carcinoma?
In the open-label, multicenter FORT-1 trial, how did the pan-FGFR inhibitor rogaratinib compare to standard chemotherapy, in terms of efficacy in treating patients with FGFR-altered urothelial carcinoma?
In the open-label, multicenter...
12/01/2022
Oncology
Quiz
Quiz: Following TURBT, which treatment was found to be a safe, effective alternative to BCG for patients with NMIBC?
10/18/2022
Following transurethral resection of bladder tumor, which treatment was found to be an effective and safe alternative to bacillus Calmete-Guérin for patients with non-muscle invasive bladder cancer?
Following transurethral resection of bladder tumor, which treatment was found to be an effective and safe alternative to bacillus Calmete-Guérin for patients with non-muscle invasive bladder cancer?
Following transurethral...
10/18/2022
Oncology
Quiz
Quiz: Radical Cystectomy vs Intravesical Therapy for Non-Muscle Invasive Bladder Cancer
09/02/2022
What was the difference in survival found between patients with non-muscle invasive bladder cancer who underwent radical cystectomy vs those who underwent intravesical therapy, within 12 months of receiving BCG?
What was the difference in survival found between patients with non-muscle invasive bladder cancer who underwent radical cystectomy vs those who underwent intravesical therapy, within 12 months of receiving BCG?
What was the difference in...
09/02/2022
Oncology
Test Your Knowledge
Quiz: Which Phase 2 Trial Led to the Approval of Sacituzumab Govitecan for aUC?
02/20/2022
The approval of sacituzumab govitecan  for patients with advanced urothelial cancer was based on which phase 2 trial?
The approval of sacituzumab govitecan  for patients with advanced urothelial cancer was based on which phase 2 trial?
The approval of sacituzumab...
02/20/2022
Oncology
Quiz
Quiz: Which Immunotherapy Drug Treats Advanced or Metastatic Urothelial Cancer?
07/01/2021
Which immunotherapy drug was recently granted accelerated approval by the FDA to treat adult patients with locally advanced or metastatic urothelial cancer?
Which immunotherapy drug was recently granted accelerated approval by the FDA to treat adult patients with locally advanced or metastatic urothelial cancer?
Which immunotherapy drug was...
07/01/2021
Oncology
Quiz
Quiz: Does Nivolumab Provide the Longest DFS Rate for Urothelial Carcinoma?
07/01/2021
In a recent trial that evaluated various treatments for patients with high-risk muscle-invasive urothelial carcinoma, adjuvant nivolumab provided the longest disease-free survival rate.
In a recent trial that evaluated various treatments for patients with high-risk muscle-invasive urothelial carcinoma, adjuvant nivolumab provided the longest disease-free survival rate.
In a recent trial that evaluated...
07/01/2021
Oncology
Test Your Knowledge
Quiz: Risk of Recurrence and Progression for Patients with NMIBC
02/19/2021
In patients with NMIBC, does high-risk recurrences and progression increase or decrease with higher tumor classification and grade at diagnosis?
In patients with NMIBC, does high-risk recurrences and progression increase or decrease with higher tumor classification and grade at diagnosis?
In patients with NMIBC, does...
02/19/2021
Oncology
Test Your Knowledge
Quiz: Which Treatment Received FDA Approval for Metastatic Urothelial Carcinoma?
11/03/2020
What treatment was approved by the FDA for metastatic urothelial carcinoma in June 2020?
What treatment was approved by the FDA for metastatic urothelial carcinoma in June 2020?
What treatment was approved by...
11/03/2020
Oncology

Recent News

News
Circulating Tumor DNA-Guided Adjuvant Atezolizumab Significantly Improves Survival Otucomes in Bladder Cancer
10/20/2025
Stephanie Holland
Adjuvant atezolizumab guided by circulating tumor DNA status led to statistically significant and clinically meaningful improvements in disease-free and overall survival compared to placebo in high-risk muscle-invasive bladder cancer.
Adjuvant atezolizumab guided by circulating tumor DNA status led to statistically significant and clinically meaningful improvements in disease-free and overall survival compared to placebo in high-risk muscle-invasive bladder cancer.
Adjuvant atezolizumab guided by...
10/20/2025
Oncology
News
Disitamab Vedotin Plus Toripalimab Doubles Survival vs Chemotherapy in HER2-Expressing Metastatic Urothelial Carcinoma
10/19/2025
Janelle Bradley
First-line treatment with disitamab vedotin plus toripalimab significantly prolonged PFS and OS compared to standard platinum-based chemotherapy in patients with HER2-expressing locally advanced or metastatic urothelial carcinoma.
First-line treatment with disitamab vedotin plus toripalimab significantly prolonged PFS and OS compared to standard platinum-based chemotherapy in patients with HER2-expressing locally advanced or metastatic urothelial carcinoma.
First-line treatment with...
10/19/2025
Oncology
News
Perioperative Enfortumab Vedotin Plus Pembrolizumab Significantly Improves Survival in Muscle-Invasive Bladder Cancer
10/19/2025
Stephanie Holland
Results from the phase 3 KEYNOTE-905/EV-303 trial show perioperative enfortumab vedotin plus pembrolizumab significantly improved survival outcomes vs surgery alone in patients with muscle-invasive bladder cancer ineligible for...
Results from the phase 3 KEYNOTE-905/EV-303 trial show perioperative enfortumab vedotin plus pembrolizumab significantly improved survival outcomes vs surgery alone in patients with muscle-invasive bladder cancer ineligible for...
Results from the phase 3...
10/19/2025
Oncology
News
Cabozantinib Plus Atezolizumab for Patients With Advanced Urothelial Carcinoma
05/13/2025
Stephanie Holland
According to results from the phase 1b COSMIC-021 trial, cabozantinib plus atezolizumab demonstrated promising clinical efficacy and safety among patients with inoperable, locally advanced or metastatic urothelial carcinoma.
According to results from the phase 1b COSMIC-021 trial, cabozantinib plus atezolizumab demonstrated promising clinical efficacy and safety among patients with inoperable, locally advanced or metastatic urothelial carcinoma.
According to results from the...
05/13/2025
Oncology
News
Sacituzumab Govitecan Fails to Significantly Improve Survival in Advanced Urothelial Carcinoma
04/17/2025
Stephanie Holland
According to final analysis results from the phase 3 TROPICS-04 trial, sacituzumab govitecan did not significantly improve survival among previously treated patients with advanced urothelial carcinoma.
According to final analysis results from the phase 3 TROPICS-04 trial, sacituzumab govitecan did not significantly improve survival among previously treated patients with advanced urothelial carcinoma.
According to final analysis...
04/17/2025
Oncology
FDA Approval
Durvalumab Approved for Muscle Invasive Bladder Cancer
03/31/2025
Allison Casey
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant...
03/31/2025
Oncology
News
Enfortumab Vedotin Demonstrates Real-World Efficacy Among Patients With Metastatic Urothelial Carcinoma
12/13/2024
Stephanie Holland
According to results from a retrospective study, single-agent enfortumab vedotin demonstrated real-world efficacy among previously treated patients with metastatic urothelial carcinoma.
According to results from a retrospective study, single-agent enfortumab vedotin demonstrated real-world efficacy among previously treated patients with metastatic urothelial carcinoma.
According to results from a...
12/13/2024
Oncology
News
Optimal Disitamab Vedotin Dose for Patients With Chemotherapy-Refractory Advanced Urothelial Carcinoma
12/13/2024
Stephanie Holland
According to results from the phase 1b/2 RC48-C014 study, the addition of 2 mg/kg of disitamab vedotin to toripalimab is preferable to 1.5 mg/kg among patients with chemotherapy-refractory locally advanced or metastatic urothelial carcinoma.
According to results from the phase 1b/2 RC48-C014 study, the addition of 2 mg/kg of disitamab vedotin to toripalimab is preferable to 1.5 mg/kg among patients with chemotherapy-refractory locally advanced or metastatic urothelial carcinoma.
According to results from the...
12/13/2024
Oncology
News
Adjuvant PD-1/-L1 Inhibition Significantly Improves Disease-Free Survival for Muscle-Invasive Urothelial Carcinoma Regardless of PD-L1 Status
12/09/2024
Stephanie Holland
Adjuvant immunotherapy with PD-1/-L1 inhibition significantly improved DFS for patients with MIUC, regardless of PD-L1 status.
Adjuvant immunotherapy with PD-1/-L1 inhibition significantly improved DFS for patients with MIUC, regardless of PD-L1 status.
Adjuvant immunotherapy with...
12/09/2024
Oncology
News
Real-World Efficacy of Enfortumab Vedotin for Patients With Advanced Urothelial Carcinoma
12/04/2024
Stephanie Holland
Results from a retrospective real-world analysis confirmed that enfortumab vedotin is a safe and effective treatment option for patients with locally advanced or metastatic urothelial carcinoma.
Results from a retrospective real-world analysis confirmed that enfortumab vedotin is a safe and effective treatment option for patients with locally advanced or metastatic urothelial carcinoma.
Results from a retrospective...
12/04/2024
Oncology
News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use